NEW YORK (GenomeWeb) – Age Labs, an Oslo-based biomarker discovery company, has been awarded €1 million (about $1.1 million) in R&D funding from the Research Council of Norway to support the development of a unique biomarker for aging.
Specifically, the company is developing a methylated DNA biomarker that will predict all-cause mortality risk and risk of developing certain age-related diseases. The company expects the biomarker to enable pharmaceutical companies to increase the probability of success in clinical trials by providing more accurate risk information about patients participating in the trials.
Age Labs is leading the four-year project, which includes collaborators AbbVie, Fürst Medical Laboratory, the Norwegian Institute of Public Health, and Oslo University.
According to its website, Age Labs applies machine learning techniques on large epigenetic datasets from Norwegian and international biobanks.